EUCTR2016-004548-12-GB进行中（未招募）1 期
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors [IGNYTE] - Phase 1/2 Study of RP1 +/- other therapies in solid tumours
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 293
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All patients:
- •1. Voluntary agreement to provide written informed consent prior to any study procedures and the willingness and ability to comply with all aspects of the protocol
- •2. Male or female = 18 years of age on the day of signed informed consent
- •3. At least one measurable (including use of image guided injection) tumor of = 1 cm in longest diameter or = 1.5 cm in shortest diameter for lymph nodes) and injectable lesions which in aggregate comprise = 1 cm in longest diameter
- •4. Females of childbearing potential must have a negative beta-human chorionic gonadotropin (ß-hCG) test with a minimum sensitivity of 25 IU/L or equivalent units of ß-hCG at screening within 72 hours before the first dose and a negative urine pregnancy test on Cycle 1 Day 1.
- •For serum and urine pregnancy tests and instructions, see Section 9.6.8.
- •5. Female patients of reproductive potential must agree to avoid becoming pregnant and
- •adhere to a highly effective contraception method until 90 days for RP1 alone or 150 days
- •for RP1 and nivolumab after last dose of study agent. For a definition of highly effective
- •contraceptive methods and instructions of patients and partners (see Section 9.6.8).
- •6. Male patients of reproductive potential must agree to avoid impregnating a partner and adhere to a highly effective contraception method until 90 days after last dose of RP1 and refrain from donating sperm during this period. For a definition of highly effective contraceptive methods and instructions of patients and partners (see Section 9.6.8).
- •7. Adequate hematologic function including:
- •a. White blood cell count (WBC) = 2.0 × 109/L
- •b. Absolute neutrophil count (ANC) = 1.5 × 109/L
- •c. Platelet count = 100 × 109/L
- •d. Hemoglobin = 9 g/dL or = 5.6 mmol/L (without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within 2 weeks of dosing)
- •8. Adequate hepatic function including:
- •a. Total bilirubin = 1.5 × upper limit of normal (ULN) (except patients with Gilbert Syndrome who must have a total bilirubin of < 3.0 × ULN) or direct bilirubin = ULN for a patient with total bilirubin level > 1.5 × ULN
- •b. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3.0 × ULN (or = 5.0 × ULN, if liver metastases)
- •c. Alkaline phosphatase (ALP) = 2.5 × ULN (or = 5.0 × ULN, if liver or bone metastases)
- •9. Adequate renal function including:
- •a. Blood creatinine = 1.5 × ULN or measured or calculated (using Cockcroft) creatinine clearance = 40 cc/minute for patients with creatinine levels > 1.5 × institutional ULN
- •10. Coagulation:
- •a. Prothrombin time (PT) or international normalization ratio (INR) = 1.5 × ULN, unless the patient is receiving anticoagulant therapy, in which case PT and partial thromboplastin time (PTT)/activated PTT (aPTT) must be within therapeutic range of intended use of anticoagulants
- •b. PTT or aPTT = 1.5 × ULN unless the patient is receiving anticoagulant therapy as long as PT and PTT/aPTT is within therapeutic range of intended use of anticoagulants
- •11. Patients must have an ECOG performance status (PS) = 1.
- •Phase 1 patients only:
- •12. Patients with histologically or cytologically confirmed advanced or metastatic non-neurological solid tumors, who have progressed on standard therapy or cannot tolerate standard therapy, or for which there is no standard therapy preferred to enrollment in a clinical trial. Note: There is no limit to the number of prior treatment regimens.
- •Phase 1 Expansion and Phase 2 patients only:
- •13. Have provid
排除标准
- •All patients:
- •1. Prior treatment with an oncolytic therapy
- •2. Has acute or chronic active hepatitis B and C virus infection or known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as HCV RNA [qualitative]) or HIV infection.
- •3. Had systemic infection requiring intravenous (IV) antibiotics or other serious infection within 14 days prior to dosing
- •4. With active significant herpetic infections or prior complications of HSV-1 infection (e.g., herpetic keratitis or encephalitis)
- •5. Systemic anticancer therapies, excluding PD1/PD-L1 directed therapy alone or in combination, within 4 weeks prior to enrollment or five half-lives, whichever is shorter, before the first administration of RP1 or has not recovered from all AEs due to previous therapies to CTCAE Grade 1 or baseline.
- •6. Conditions requiring treatment with immunosuppressive doses (> 10 mg daily prednisone or equivalent) of systemic corticosteroids other than for corticosteroid replacement therapy within 14 days of enrollment. For the definition of replacement therapy, see Section 7.3.
- •7. Active leptomeningeal disease or uncontrolled, untreated brain metastasis:
- •Patients with a history of treated brain metastasis and, at the time of screening,
- •asymptomatic stable central nervous system (CNS) metastases are eligible, provided they meet all the following:
- •a. Brain imaging at screening shows no evidence of interim progression for at least 4 weeks by repeat imaging, and clinically stable for at least 2 weeks
- •b. Have measurable disease outside the CNS
- •c. Only supratentorial metastases allowed
- •d. No ongoing requirement for corticosteroids as therapy for CNS disease; anticonvulsants at a stable dose allowed
- •e. No stereotactic or whole-brain radiation within 14 days prior to enrollment
- •8. Major surgery = 2 weeks prior to starting study drug. Note: If patient received major surgery, he or she must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.
- •9. Any active malignancy = 3 years before enrollment except for the specific cancer under investigation in this study and locally recurring cancer that has been treated curatively (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma
- •in situ of the prostate, cervix, or breast)
- •10. Female who has a positive serum pregnancy test (at screening within 72 hours before dosing) or urine pregnancy test (Cycle 1 Day1) or is breastfeeding or planning to become pregnant during study treatment or within 90 days (RP1 alone) or 150 days (RP1 and nivolumab) after the last dose of study treatment
- •11. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
- •12. History of interstitial lung disease
- •13. History of documented allergic reactions or acute hypersensitivity reaction attributed to RP1 or nivolumab or any of its excipients.
- •14. Has received prior radiotherapy within 2 weeks of start of study treatment. Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.
- •15. Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox
研究者
相似试验
进行中（未招募）
1 期
Study of RP1 alone and in combination with other therapies in patients with solid tumoursEUCTR2016-004548-12-ESReplimune Inc.300
尚未招募
不适用
An open-label, multicenter, phase II study of PDR001 in patients with non-small cell lung cancer harboring KRAS/NRAS mutation or without actionable genetic abnormalities, detected using NGS platformKCT0002975Asan Medical Center70
已完成
不适用
Phase Ib, multicenter, open label study of PDR001 in combination with platinum-doublet chemotherapy in PD-L1 unselected, metastatic NSCLC patientsnon small cell lung cancer1003866610028971lung cancerNL-OMON45593ovartis6
已完成
2 期
Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphomaJPRN-jRCT2080223865ovartis Pharma. K.K.9
招募中
1 期
An Open-Label, Multicenter Study of the Safety and Efficacy in Subjects with Relapsed/Refractory Myelofibrosis and in Janus-associated Kinase Inhibitor-Intolerant MyelofibrosisRelapsed/Refractory Myelofibrosis and Janus-associated Kinase Inhibitor-Intolerant MyelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-002392-35-FRKartos Therapeutics, Inc.116